Clinical studies are about to get underway at an Australia university, to track changes in actual dementia patients to see if cannabis can help with dementia and related issues

The study will be led by the Institute for Health Research at the University of Notre Dame in Perth. As Australia’s 7News reports, the research team is currently screening candidates for the study, which will use lab-grown cannabis from Slovenia. The researchers are especially hoping the CBD-heavy strain will reduce the most deleterious and troubling effects of dementia.

In the Australian clinical study, cannabinoids will be extracted and delivered in a mouth spray, making it easier to be administered to the elderly. The spray will be produced by MGC Pharmaceuticals, an Australian firm founded by Israeli researchers.

The clinical trial will be held over a 14-month period starting early next year. It will involve 50 participants aged 65 years and older who have mild dementia and who currently live in an accredited residential aged-care facility.

Study leader Amanda Timler told the West Australian newspaper she believes that cannabis “works well with a lot of behavioral and neuro-psychotic symptoms associated with dementia, such as aggression and agitation. Medicinal cannabis is also thought to increase appetite as well as improve sleep cycles.”

She added to Australia’s morning TV news show Sunrise: “We think cannabis is going to help ameliorate behavioral signs and symptoms we see from dementia. It’s one of those medications that will treat a number of symptoms compared with typically being diagnosed with dementia and taking a number of different drugs.”

Read full report